MPM Bioimpact LLC Acquires 96,856 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

MPM Bioimpact LLC grew its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 19.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 589,579 shares of the company’s stock after buying an additional 96,856 shares during the period. Mirum Pharmaceuticals makes up approximately 3.5% of MPM Bioimpact LLC’s investment portfolio, making the stock its 6th largest holding. MPM Bioimpact LLC’s holdings in Mirum Pharmaceuticals were worth $24,379,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Jones Financial Companies Lllp increased its position in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after buying an additional 357 shares in the last quarter. R Squared Ltd purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at $69,000. AlphaQuest LLC increased its position in shares of Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after buying an additional 1,658 shares in the last quarter. Summit Investment Advisors Inc. increased its position in shares of Mirum Pharmaceuticals by 8.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company’s stock valued at $172,000 after buying an additional 312 shares in the last quarter. Finally, Avanza Fonder AB purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at $189,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $45.27 on Wednesday. The firm has a market capitalization of $2.24 billion, a P/E ratio of -22.41 and a beta of 0.95. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.83 and a 1-year high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The business’s 50-day simple moving average is $42.88 and its 200-day simple moving average is $44.35.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.05. The firm had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Mirum Pharmaceuticals’s revenue for the quarter was up 61.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.54) EPS. Equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 57,606 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the sale, the senior vice president now directly owns 4,841 shares in the company, valued at $214,698.35. The trade was a 92.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Peter Radovich sold 7,879 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $348,330.59. Following the sale, the chief operating officer now owns 18,672 shares in the company, valued at $825,489.12. This represents a 29.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 92,764 shares of company stock valued at $4,109,161. Corporate insiders own 14.36% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on MIRM. Raymond James increased their price objective on Mirum Pharmaceuticals from $73.00 to $77.00 and gave the company a “strong-buy” rating in a research note on Tuesday. JMP Securities raised their price target on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a “market outperform” rating in a research note on Friday, May 9th. HC Wainwright raised their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Finally, Robert W. Baird raised their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $60.64.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.